Workbook sheet
Insurance, prior authorization, and step therapy
Prior authorization is a plan’s request for evidence before it pays. It is not a medical diagnosis, and a denial is not proof the drug is unsafe. Step therapy is a related rule: the plan wants another treatment tried first. This sheet is a list of questions and a summary of what CMS has published about Medicare. It cannot see your card. The clinical path that produces the prescription is described on how a GLP-1 prescription starts. Which brand matches which indication is on the class map.
Start with the indication, because plans do
Wegovy’s label includes weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and an accelerated-approval use in noncirrhotic MASH. Zepbound’s label includes adult weight reduction and moderate to severe obstructive sleep apnea in adults with obesity. Ozempic and Mounjaro include type 2 diabetes indications. A plan that covers a diabetes GLP-1 and excludes weight-management drugs can approve one prescription and deny the other without contradicting itself. When the prescriber sends the prescription, the diagnosis they attach should match the use they intend. If you are being treated for sleep apnea, a weight-only code can send the claim down the wrong path. If you are being treated to reduce cardiovascular risk, a weight-only code can do the same.
Ask the plan, or read the formulary:
- Is this specific drug and form on formulary for the indication being prescribed?
- Is prior authorization required? Step therapy? A quantity limit?
- What documents does the plan want: BMI, comorbidity list, previous medicines, notes from a diet program?
- How is the request submitted, and how many days does the plan state for a decision?
- If it is denied, where is the appeal address, and is there an expedited option?
Write down the date and the name of the person or the page. “They cover GLP-1s” is not a note you can appeal from.
Commercial plans and the paperwork they often ask for
Commercial formularies differ. Many require prior authorization for Wegovy or Zepbound when the use is weight management, and many ask for a BMI in the range the plan sets, which can be stricter than the FDA indication. Some ask for a history of a structured lifestyle program. Some require step therapy through an older weight-management drug. None of those plan rules rewrite the label. They rewrite who the plan will pay for. Your clinician can complete the form only if the chart actually contains the facts the plan wants. A visit note that never records weight, height, and the comorbid condition will stall a request that asks for all three.
Quantity limits matter because these drugs are packaged as 28-day supplies. A plan that allows one box per 28 days will reject an early refill. Escalation means the strength changes. The new strength is often a new prescription, not a refill of the old one. Pharmacies see that as a new claim, and prior authorization sometimes has to be redone for the new strength. Ask before the week you are supposed to step up, not on the morning the pen is empty.
Employer plans can exclude weight-management drugs entirely, even when they cover diabetes drugs. That exclusion is a benefit design. It is not fixed by a prior authorization. If the exclusion is real, the useful next sheets are savings offers and cash prices, not a third appeal of a benefit the plan does not have.
Medicare Part D and the GLP-1 Bridge
CMS has described two different doors, and mixing them up is how prescriptions get stuck.
For uses CMS treats as coverable under Part D, the claim goes to the Part D plan. CMS’s provider page says type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic MASH are eligible for Part D coverage, and that beneficiaries with those diagnoses get the drug through the plan rather than through the Bridge. The same page says that if the drug is being prescribed to reduce the risk of major adverse cardiovascular events, the prescription should be routed to the Part D plan, even if weight reduction is also a goal. Plans still use their own formularies and exception processes. Coverage of a Part D-eligible use is not automatic on every plan’s list. The plan’s exception process is the route when the drug is not on formulary.
Separately, CMS is running a Medicare GLP-1 Bridge, a Section 402 demonstration from July 1, 2026, through December 31, 2027. It sits outside the Part D payment flow. Part D sponsors do not have to opt in for a beneficiary to use it. CMS says it uses a central processor for prior authorization, claims, and pharmacy payment. The Bridge is for eligible Part D beneficiaries who use specified GLP-1 drugs to reduce excess body weight and maintain weight reduction, and who meet published clinical criteria. As of the provider page reviewed on November 18, 2026, the products named for the Bridge were Foundayo, Wegovy injection and tablets, and Zepbound KwikPen. Zepbound vials and single-dose pens were not included. Pen needles for the KwikPen are not covered by the Bridge.
The clinical criteria on that page, which a prescriber attests to, require that the drug be prescribed for weight reduction together with lifestyle modification consistent with the label, and one of the following at the time GLP-1 therapy was initiated: age 18 or older with BMI at least 35; or BMI at least 30 with heart failure with preserved ejection fraction, uncontrolled hypertension despite two antihypertensives, or chronic kidney disease stage 3a or above; or BMI at least 27 with prediabetes as defined by the American Diabetes Association, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease. CMS says the criteria are applied at initiation, so a later lower BMI does not erase a qualifying starting BMI. There is a copay figure on the page: eligible GLP-1s are furnished under the Bridge with a $50 copay when prescribed for a weight-management indication. Confirm that figure on the CMS page before you budget it. Demonstration terms can be updated.
Not every Medicare beneficiary is in an eligible plan type. The provider page lists standalone PDPs and Medicare Advantage coordinated-care plans with drug coverage, and it lists plan types that are not eligible unless the person also has a qualifying PDP. Read that section rather than assuming every Medicare card works. The prescriber does not have to be enrolled in Medicare to prescribe under the Bridge, and must not be on the Preclusion List. Prior authorization is required. CMS says the prescriber should send the prescription to the pharmacy first and wait for the pharmacy to request prior authorization. Submitting the form before a claim exists can return “patient not found.” Decisions are described as going to the patient by mail and to the prescriber by portal or fax within 72 hours. There is no appeals process. A prescriber who entered the form wrong may resubmit. That is not the same as a Part D appeal.
A 2024–2025 CMS fact sheet discussed a proposal to reinterpret the statutory exclusion of agents used for weight loss so that anti-obesity medicines could be covered under Part D for obesity itself. That fact sheet describes a proposal. Do not quote it as the rule that replaced the Bridge. The operational document for weight-management access in Medicare, as reviewed for this sheet, is the Bridge page, alongside Part D coverage for the non-weight indications named above.
What to bring to the clinician who has to sign the form
Height, weight, and the date they were measured. The list of conditions with roughly when they were diagnosed. Current medicines, including any GLP-1 product already tried. Whether you are on Medicare, Medicaid, TRICARE, or a commercial card, because savings offers and the Bridge exclude or include those programs differently. A copy of the denial if you already have one. The denial sheet is the next step when the paper already says no.
Prior authorization is slow when the chart is thin and faster when the indication, the BMI, and the plan’s checklist are the same story. It is still the plan’s decision. This workbook cannot file it for you.
Sources checked for this sheet
- https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
- https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
- https://glp1.here/guides/how-to-get-a-glp-1-prescription
- https://glp1meds.org/monographs/which-glp-1-medicines